Noramco

Noramco is a globally integrated leader in the development and manufacture of controlled substance APIs, serving pharmaceutical companies in the ADHD, pain management, and addiction treatment markets. Its key strategic advantages include backward integration through its sister company Tasmanian Alkaloids, providing secure access to premium narcotic raw materials, and extensive DEA-compliant manufacturing capacity in the US and Europe. The company has recently formed the Noramco Group with Purisys and Halo Pharma to offer integrated API and drug product supply chain services, positioning itself as a critical, onshore supplier in a geopolitically sensitive sector.

Vertically integrated controlled substance API platform featuring proprietary narcotic raw material sourcing from patented poppies, DEA-compliant cGMP manufacturing at scale, and particle engineering for formulation support.

Noramco competes with a small number of specialized API manufacturers capable of handling controlled substances at scale, such as Mallinckrodt's SpecGx and Johnson Matthey's former API business. Its key competitive advantages are vertical integration with raw materials and its integrated service offering through the Noramco Group.